Dynavax To Seek Experienced Vaccines Partner To Commercialize Heplisav
This article was originally published in The Pink Sheet Daily
Executive Summary
The company reports positive Phase III data for the hepatitis B vaccine showing 98.5% seroprotection after two doses.
You may also be interested in...
Merck And Dynavax Pair Up For Heplisav
Data from international Phase III study of the novel hepatitis B vaccine remain on track for first half 2008, Dynavax CEO Dina says.
Merck And Dynavax Pair Up For Heplisav
Data from international Phase III study of the novel hepatitis B vaccine remain on track for first half 2008, Dynavax CEO Dina says.
Dynavax’ Heplisav Phase III Data Bolsters Hep B Seroprotection Claims
Long-term data from study comparing Heplisav to GSK's Engerix-B shows 100 percent seroprotection 50 weeks post-vaccination.